CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 17 enrolled
Drug / intervention
PCV13 +1 morebiological
Likely dose
PCV13 0.5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03260790
NCT03260790Phase 4Completed
CompareCT.gov

Immunogenicity of PPSV-23 After PCV-13 Vaccination in Adult Asthmatic Patients

Mayo Clinic·interventional·Posted Aug 24, 2017·Updated Nov 5, 2021

In Brief

A Phase 4 clinical trial evaluating PCV13 and PPSV23 for Asthma. Completed, enrolled 17 participants across 1 site.

Detailed Summary

Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedAug 24, 2017
Enrollment StartOct 1, 2017
Primary CompletionDec 21, 2020
Study CompletionDec 25, 2020
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 8.9 years ago

Interventions

PCV13biological

Single 0.5 ml dose of PCV13 administered via intramuscular injection

PPSV23biological

Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously